Luspatercept combined with low-dose thalidomide
2025-K0444
Phase 2 small_molecule active
Quick answer
Luspatercept combined with low-dose thalidomide for Transfusion-dependent β-thalassemia Patients is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Transfusion-dependent β-thalassemia Patients
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active